10
Participants
Start Date
February 15, 2024
Primary Completion Date
September 3, 2024
Study Completion Date
September 3, 2024
Placebo
Placebo
Active
Sisunatovir
University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA), Johannesburg
Monti Clinical Research Centre, Mdantsane
Washington University School of Medicine, St Louis
Kaiser Permanente Los Angeles Medical Center, Los Angeles
Kaiser Permanente, Los Angeles
Kojunkai Daido Hospital, Nagoya
Nintenkai Kagoshima Children's Hospital, Hioki
Yamanashi Prefectural Central Hospital, Kofu
Osaka City General Hospital, Osaka
Lead Sponsor
Pfizer
INDUSTRY